Prokidney (PROK) Asset Writedowns and Impairment (2024 - 2025)
Prokidney's (PROK) quarterly Asset Writedowns and Impairment came in at $318000.0 in Q3 2025, down 94.03% year-over-year from $5.3 million in Q3 2024, and down 94.03% quarter-over-quarter from $5.3 million in Q3 2024.
Powered by 
Analysis
Prokidney (PROK) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Prokidney (PROK) has reported Asset Writedowns and Impairment for 2 consecutive years, with $318000.0 the latest figure, recorded in Q3 2025.
- On a quarterly basis, Asset Writedowns and Impairment fell 94.03% year-over-year to $318000.0 in Q3 2025; TTM through Dec 2025 was $318000.0, a 94.03% decrease from a year earlier, with the FY2025 full-year figure at $318000.0, down 94.03% from the prior year.
- Asset Writedowns and Impairment was $318000.0 for Q3 2025 at Prokidney, down from $5.3 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $5.3 million in Q3 2024 and troughed at $318000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Prokidney | 346.07 Mn | 346.07 Mn | - |